<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00777244</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2007-007262-38</org_study_id>
    <nct_id>NCT00777244</nct_id>
  </id_info>
  <brief_title>Efficacy of Adjuvant Mitotane Treatment (ADIUVO)</brief_title>
  <acronym>ADIUVO</acronym>
  <official_title>Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Rationale Adrenocortical carcinoma (ACC) is a very rare disease with a high risk of
      relapse after radical surgery. The efficacy of adjuvant mitotane treatment is suggested by a
      retrospective multicenter international study showing that postoperative mitotane treatment
      was associated with a significant reduction of the risk of relapse and death. However, these
      promising results need confirmation in a randomized prospective study. Caution should be
      adopted particularly in patients with low risk of disease relapse, in whom the benefit of
      therapy should be weighted against the side effects. Even if an adjuvant treatment seems
      justified in patients at high risk of relapse, a randomised prospective study is needed to
      assess whether such a treatment is efficacious in patients at low-intermediate risk.

      The purpose of the present study is to determine whether adjuvant mitotane treatment is
      effective in prolonging the disease free survival in patients with adrenocortical carcinoma
      at low-intermediate risk of progression who underwent radical resection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endpoints Primary : To compare DFS (Disease Free Survival), defined as the time between the
      date of randomization until documentation of any of the following failures (whichever occurs
      first): -local or distant recurrence of disease;-death from any cause or completion of
      follow-up.

      Secondary:

      To compare OS (Overall Survival), defined as the time interval between the date of
      randomization and the date of death from any cause or the last known alive date;· To compare
      quality of life measured by EORTC-QLQ-C30· To compare toxicity, graded according to the
      NCI-CTG criteria;· To compare DFS and OS in patients who achieve or not serum mitotane
      concentrations &gt; 14 mg/L;· To compare DFS and OS between the 2 arms in patients subgroups
      stratified according to: type of hormone secretion, stage of disease, histopathologic
      characteristics.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free survival</measure>
    <time_frame>Till the last follow up</time_frame>
    <description>Survival in years</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Adrenocortical Carcinoma</condition>
  <arm_group>
    <arm_group_label>Follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Arm B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mitotane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MITOTANE</intervention_name>
    <description>mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance on day 2 to 3 g/day, on day 3 to 4.5 g/day, and on day 4 to 6 g/day. A dose of 6 g/day will be administered until first mitotane blood level is assessed. Further adjustment of dosage will be performed according to blood concentrations and tolerability.</description>
    <arm_group_label>Mitotane</arm_group_label>
    <other_name>Mitotane (Lysodren)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of ACC according to Weiss system by a national
             reference pathologist who has to be nominated before study initiation.

          -  Low-intermediate risk of relapse defined as:

               -  Stage I-III (according to ENSAT classification 2008; see Appendix 2)

               -  Microscopically complete resection, defined as no evidence of microscopic
                  residual disease based on surgical reports, histopathology and post-operative
                  imaging. Detailed pathological and surgical reports prepared according to
                  guidelines detailed in appendix x and y should be available for assessment.

               -  Ki 67 &lt; 10%

          -  Post-operative imaging (thoracic and whole abdominal CT with contrast medium or MRI)
             demonstrating no evidence of disease within 4 weeks from randomization

          -  Age &gt; 18 years

          -  ECOG performance status 0-2 (Appendix 3)

          -  Adequate bone marrow reserve (neutrophils &gt; 1000/mm3 and platelets &gt; 80000/ mm3)

          -  Ability to comply with the protocol procedures (including geographic accessibility)

          -  Written informed consent

        Exclusion Criteria:

          -  Time between primary surgery and randomization &gt; 3 months.

          -  Repeat surgery for recurrence of disease

          -  Presence of autonomous adrenocortical hormone secretion despite the absence of disease
             detectable with imaging techniques

          -  History of prior malignancy, except for cured non-melanoma skin cancer, cured in situ
             cervical carcinoma, or other treated malignancies with no evidence of disease for at
             least three years

          -  Renal insufficiency (creatinine clearance &lt; 40 ml/min) or liver insufficiency (serum
             bilirubin &gt; 2 times the upper normal range and/or serum transaminases (AST/SGOT,
             ALT/SGPT, but not gamma Glutamyl Transpeptidase) &gt;3 times the upper normal range).
             Creatinine clearance may be calculated according to validated formulas (Crockoft's or
             MDRD)

          -  Pregnancy or breast feeding

          -  Previous or current treatment with mitotane or other antineoplastic drugs for ACC

          -  Previous radiotherapy of the tumor bed (for ACC).

          -  Any other severe acute or chronic medical or psychiatric condition, or laboratory
             abnormality that would impart, in the judgment of the investigator, excess risk
             associated with study participation or study drug administration, or which, in the
             judgment of the investigator, would make the patient inappropriate for entry into this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Terzolo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Fassnacht, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Internal Medicine, University of Wuerzburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfredo Berruti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical Oncology, Department of Clinical and Biological Sciences, University of Turin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Baudin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncologie Endocrinienne et Médecine Nucléaire, Institut Gustave Roussy, Villejuif, France.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harm Haak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine, Máxima Medical Centre, Eindhoven, The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Perotti</last_name>
    <phone>+390119026</phone>
    <phone_ext>643</phone_ext>
    <email>oncotrial.sanluigi@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paola Sperone</last_name>
    <phone>+390119026</phone>
    <phone_ext>017</phone_ext>
    <email>paola.sperone@email.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Oncology Branch - Center for Cancer Research - National Cancer Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tito Fojo</last_name>
      <email>fojot@mail.nih.gov</email>
    </contact>
    <contact_backup>
      <last_name>Maureen Edgerly</last_name>
      <phone>301-435</phone>
      <phone_ext>5604</phone_ext>
      <email>edgerlym@mail.nih.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Tito Fojo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrine Oncology - University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0921</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Endocrinologie - Centre hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <zip>3840</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>André Lacroix</last_name>
      <email>andre.lacroix@umontreal.ca</email>
    </contact>
    <investigator>
      <last_name>André Lacroix</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrinologie - CHU Besançon Hôpital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfred Perforinis</last_name>
      <email>alfred.penfornis@univ-fcomte.fr</email>
    </contact>
    <contact_backup>
      <last_name>Annie Clergeot</last_name>
      <email>aclergeot@chu-besancon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Alfred Penfornis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrinologie - CHU Lyon Hôpital Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Pugeat</last_name>
      <email>michel.pugeat@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Cecilie Nozieres</last_name>
      <email>cecile.nozieres@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Michel Pugeat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrinologie - Hôpital A. Michallon</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Cabre</last_name>
      <phone>33 04 76 76</phone>
      <phone_ext>5175</phone_ext>
      <email>OlivierChabre@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Cabre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrinologie - Cochin, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertagna Xavier</last_name>
      <phone>+330158</phone>
      <phone_ext>411790</phone_ext>
      <email>xavier.bertagna@cch.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Rossella Libè</last_name>
      <phone>+330158</phone>
      <phone_ext>413249</phone_ext>
      <email>Emrossella.libe@cch.aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Xavier Bertagna</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rossella Libè</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrinologie - CHU Toulouse Hôpital Larrey</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Caron</last_name>
      <email>caron.p@chu-toulouse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Delphine Vezzosi</last_name>
      <email>vezzosi.d@chu-toulouse.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Philippe Caron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrinologie - Institut de Cancérologie Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Baudin</last_name>
      <phone>+330142</phone>
      <phone_ext>114242</phone_ext>
      <email>eric.baudin@igr.fr</email>
    </contact>
    <contact_backup>
      <last_name>Cécile CHOUGNET</last_name>
      <phone>+330142</phone>
      <phone_ext>115224</phone_ext>
      <email>Cecile.chougnet@igr.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Baudin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Campus Mitte Charitè, Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus PD Quinkler</last_name>
      <phone>030-450</phone>
      <phone_ext>514259</phone_ext>
      <email>marcus.quinkler@charite.de</email>
    </contact>
    <investigator>
      <last_name>Marcus Quinkler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Bornstein, MD</last_name>
      <phone>0351-458</phone>
      <phone_ext>5955</phone_ext>
      <email>stefan.bornstein@uniklinikum-dresden.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Bornstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40001</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Holger Willenberg, MD</last_name>
      <email>Holger.Willenberg@uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Holger Willenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Endocrine Tumors - ENDOC</name>
      <address>
        <city>Hamburg</city>
        <zip>20357</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Petersenn, MD</last_name>
      <phone>040-401</phone>
      <phone_ext>87985</phone_ext>
      <email>stephan.petersenn@endoc-med.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Petersenn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medicin Centre of Munchen</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felix Beuschlein, MD</last_name>
      <phone>089 -5160</phone>
      <phone_ext>2110</phone_ext>
      <email>felix.beuschlein@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Martin Fassnacht</last_name>
      <email>Fassnacht_m@medizin.uni-wuerzburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Felix Beuschlein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Wuerzburg, Endocrinology</name>
      <address>
        <city>Wurzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin MD Fassnacht</last_name>
      <phone>0931-201-</phone>
      <phone_ext>39021</phone_ext>
      <email>Fassnacht_M@medizin.uni-wuerzburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Sculler</last_name>
      <email>Schuller_P@medizin.uni-wuerzburg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Fassnacht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.Universitaria Arcispedale S.Anna Ferrara</name>
      <address>
        <city>Ferrara</city>
        <state>Fe</state>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Ettore Degli Uberti</last_name>
    </contact>
    <investigator>
      <last_name>Ettore Degli Uberti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Oncologia Medica - AO Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfredo Berruti</last_name>
      <email>alfredo.berruti@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Anna Scalvini</last_name>
      <email>annascalvini@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alfredo Berruti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università degli studi di Firenze</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Massimo Mannelli</last_name>
    </contact>
    <investigator>
      <last_name>Massimo Mannelli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Foggia</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Cà Granda-Niguarda-Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Loli</last_name>
    </contact>
    <investigator>
      <last_name>Paola Loli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Luigi</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Perotti</last_name>
      <phone>+390119026</phone>
      <phone_ext>017</phone_ext>
      <email>oncotrial.sanluigi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Clinical and Biological Sciences, University of Turin, Internal Medicine 1</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Perotti</last_name>
      <phone>+390119026</phone>
      <phone_ext>513</phone_ext>
      <email>oncotrial.sanluigi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Massimo Terzolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Università degli studi di Palermo</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vittorio Gebbia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O.U. San Giovanni Battista - Molinette</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enzo Gigo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Enzo Ghigo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Internal Medicine Maxima Medisch Centrum</name>
      <address>
        <city>Eindhoven</city>
        <zip>5600 PD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Harm Haak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Research UK Clinical Trials Unit (CRCTU) - School of Cancer Sciences - University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Edgbaston</state>
        <zip>152TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wiebke Arlt</last_name>
      <email>w.arlt@bham.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Ana Huges</last_name>
      <email>a.i.hughes@bham.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Wiebke Arlt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.epiclin.it/adiuvo</url>
    <description>study website</description>
  </link>
  <reference>
    <citation>Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, Saeger W, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L, Berruti A. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007 Jun 7;356(23):2372-80.</citation>
    <PMID>17554118</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2008</study_first_submitted>
  <study_first_submitted_qc>October 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2008</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Turin, Italy</investigator_affiliation>
    <investigator_full_name>Alfredo Berruti</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>mitotane</keyword>
  <keyword>adjuvant therapy</keyword>
  <keyword>disease free survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitotane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

